Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, Others), By Application (Leukemia, Lymphoma, Multiple Myeloma, Others), By End User (Hospitals & Specialty Clinics, Academic & Research Institutions, Clinical Laboratories, Others), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: MA69DB09C27BEN
TechSci Research

Abstracts

The Global Minimal Residual Disease (MRD) Testing Market, valued at USD 1.45 Billion in 2024, is projected to experience a CAGR of 8.70% to reach USD 2.39 Billion by 2030. Minimal residual disease (MRD) testing identifies minute quantities of cancer cells remaining in a patient's body post-treatment, often undetectable by conventional methods, which significantly predict disease relapse. This global market's expansion is fundamentally driven by the rising incidence of various hematological malignancies and continuous advancements in diagnostic technologies, such as next-generation sequencing and highly sensitive flow cytometry.

Key Market Drivers

The escalating global incidence of cancer and hematological malignancies represents a primary force propelling the minimal residual disease testing market. As the population grows and ages, the number of new cancer diagnoses continues to rise, directly increasing the patient pool requiring sophisticated monitoring tools throughout their treatment journey and follow-up. MRD testing becomes crucial in managing these conditions by offering precise detection of residual disease after therapy, guiding subsequent treatment decisions, and identifying patients at high risk of relapse.

Key Market Challenges

The high cost associated with advanced minimal residual disease testing technologies represents a significant impediment to market expansion. These economic considerations directly limit patient access and hinder widespread adoption, especially in healthcare systems facing budget constraints or where high patient out-of-pocket expenses are prevalent. The advanced methodologies and specialized infrastructure required for these tests contribute to their elevated cost, thereby making them less attainable for a wider patient demographic.

Key Market Trends

The expanding clinical utility of minimal residual disease (MRD) testing in solid tumors represents a significant market trend, moving beyond its established role in hematological malignancies. This shift is driven by the clear need for more precise post-treatment monitoring and recurrence prediction in a broader patient population. According to the American Cancer Society, in 2023, an estimated 1,958,310 new cancer cases were projected to occur in the United States, with solid tumors constituting the vast majority of these diagnoses, highlighting a substantial and underserved patient base for advanced monitoring solutions. This expansion is further underscored by industry developments, such as Illumina Inc. 's announcement in January 2024 of a collaboration with Janssen Research & Development, LLC to develop a novel molecular residual disease assay. This whole-genome sequencing multi-cancer research solution is specifically designed to detect circulating tumor DNA for various solid tumor indications, signaling growing investment and technological application in this area.

Key Market Players

• ICON plc
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Cergentis B.V.
• OPKO Health, Inc.
• Sysmex Corporation
• Mission Bio, Inc.
• Invivoscribe, Inc.

Report Scope:

In this report, the Global Minimal Residual Disease (MRD) Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Minimal Residual Disease (MRD) Testing Market, By Technology:
• Flow Cytometry
• Polymerase Chain Reaction
• Next Generation Sequencing
• Others
• Minimal Residual Disease (MRD) Testing Market, By Application:
• Leukemia
• Lymphoma
• Multiple Myeloma
• Others
• Minimal Residual Disease (MRD) Testing Market, By End User:
• Hospitals & Specialty Clinics
• Academic & Research Institutions
• Clinical Laboratories
• Others
• Minimal Residual Disease (MRD) Testing Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Minimal Residual Disease (MRD) Testing Market.

Available Customizations:

Global Minimal Residual Disease (MRD) Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, Others)
  5.2.2. By Application (Leukemia, Lymphoma, Multiple Myeloma, Others)
  5.2.3. By End User (Hospitals & Specialty Clinics, Academic & Research Institutions, Clinical Laboratories, Others)
  5.2.4. By Region
  5.2.5. By Company (2024)
5.3. Market Map

6. NORTH AMERICA MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Technology
  6.2.2. By Application
  6.2.3. By End User
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Minimal Residual Disease (MRD) Testing Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Technology
      6.3.1.2.2. By Application
      6.3.1.2.3. By End User
  6.3.2. Canada Minimal Residual Disease (MRD) Testing Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Technology
      6.3.2.2.2. By Application
      6.3.2.2.3. By End User
  6.3.3. Mexico Minimal Residual Disease (MRD) Testing Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Technology
      6.3.3.2.2. By Application
      6.3.3.2.3. By End User

7. EUROPE MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Technology
  7.2.2. By Application
  7.2.3. By End User
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Minimal Residual Disease (MRD) Testing Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Technology
      7.3.1.2.2. By Application
      7.3.1.2.3. By End User
  7.3.2. France Minimal Residual Disease (MRD) Testing Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Technology
      7.3.2.2.2. By Application
      7.3.2.2.3. By End User
  7.3.3. United Kingdom Minimal Residual Disease (MRD) Testing Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Technology
      7.3.3.2.2. By Application
      7.3.3.2.3. By End User
  7.3.4. Italy Minimal Residual Disease (MRD) Testing Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Technology
      7.3.4.2.2. By Application
      7.3.4.2.3. By End User
  7.3.5. Spain Minimal Residual Disease (MRD) Testing Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Technology
      7.3.5.2.2. By Application
      7.3.5.2.3. By End User

8. ASIA PACIFIC MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Technology
  8.2.2. By Application
  8.2.3. By End User
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Minimal Residual Disease (MRD) Testing Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Technology
      8.3.1.2.2. By Application
      8.3.1.2.3. By End User
  8.3.2. India Minimal Residual Disease (MRD) Testing Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Technology
      8.3.2.2.2. By Application
      8.3.2.2.3. By End User
  8.3.3. Japan Minimal Residual Disease (MRD) Testing Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Technology
      8.3.3.2.2. By Application
      8.3.3.2.3. By End User
  8.3.4. South Korea Minimal Residual Disease (MRD) Testing Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Technology
      8.3.4.2.2. By Application
      8.3.4.2.3. By End User
  8.3.5. Australia Minimal Residual Disease (MRD) Testing Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Technology
      8.3.5.2.2. By Application
      8.3.5.2.3. By End User

9. MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Technology
  9.2.2. By Application
  9.2.3. By End User
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Minimal Residual Disease (MRD) Testing Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Technology
      9.3.1.2.2. By Application
      9.3.1.2.3. By End User
  9.3.2. UAE Minimal Residual Disease (MRD) Testing Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Technology
      9.3.2.2.2. By Application
      9.3.2.2.3. By End User
  9.3.3. South Africa Minimal Residual Disease (MRD) Testing Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Technology
      9.3.3.2.2. By Application
      9.3.3.2.3. By End User

10. SOUTH AMERICA MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Technology
  10.2.2. By Application
  10.2.3. By End User
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Minimal Residual Disease (MRD) Testing Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Technology
      10.3.1.2.2. By Application
      10.3.1.2.3. By End User
  10.3.2. Colombia Minimal Residual Disease (MRD) Testing Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Technology
      10.3.2.2.2. By Application
      10.3.2.2.3. By End User
  10.3.3. Argentina Minimal Residual Disease (MRD) Testing Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Technology
      10.3.3.2.2. By Application
      10.3.3.2.3. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL MINIMAL RESIDUAL DISEASE (MRD) TESTING MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. ICON plc
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche AG
15.3. Bio-Rad Laboratories, Inc.
15.4. Laboratory Corporation of America Holdings
15.5. Natera, Inc.
15.6. Cergentis B.V.
15.7. OPKO Health, Inc.
15.8. Sysmex Corporation
15.9. Mission Bio, Inc.
15.10. Invivoscribe, Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER